



Keywords: Vitamin D; Preeclampsia; Gestation; Pregnancy; Endothelial dysfunction

Introduction

Preeclampsia is a life threatening pregnancy disorder, which is classically characterised by hypertension and proteinuria and complicates 2-8% of all pregnancies [1]. The pathophysiology of preeclampsia is poorly understood, however, it is often described as a 2-stage process whereby Stage I is characterised by abnormal placental invasion and formation resulting in impaired placental perfusion. It is thought that reactive oxygen species and pro-inflammatory cytokines released from the ischaemic placenta result in oxidative stress and placental endothelial cell dysfunction [2,3]. This creates a pathophysiological state resulting in Stage II of preeclampsia with the clinical detection of hypertension, proteinuria and eventual organ damage [2].

In recent times, it has become increasingly evident that preeclampsia is no longer an isolated disease of pregnancy, but rather has a significant impact on the risk of subsequent maternal and paediatric cardiovascular disease [4,5]. Preeclampsia has been shown to be an independent risk factor for maternal cardiovascular disease 10 to 15 years after the affected pregnancy, with an increase in the risk of cardiovascular disease of similar magnitude to that of dyslipidaemia [4,6]. Furthermore, children of preeclamptic pregnancies have been found to have elevated blood pressure and increased cardiovascular risk later in life [7].

Recent studies have demonstrated that in preeclamptic placentas there is increased expression of this catabolyzing enzyme, suggesting elevated degradation of active vitamin D in these placentas as compared to healthy placentas [3]. Furthermore, researchers have found reduced expressions of VDR and DBP in preeclamptic placentas as compared to normal placentas, providing direct evidence of disrupted vitamin D metabolism in the preeclamptic placenta [3].

Although the exact molecular mechanisms by which vitamin D deficiency affects the risk of developing preeclampsia is yet to be determined, there are a number of potential avenues by which they are hypothesised to occur. Reduced placental perfusion during Stage I may result in the placenta producing substances, including pro-inflammatory cytokines that initiate the ensuing multi-system sequelae characterising Stage II of preeclampsia [17,19]. Pro-inflammatory

Citation:

Citation: Arsala L, Silva Costa FD, Murthi P,